Safety and Efficacy of Combigan® Ophthalmic Solution in Korea
Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Glaucoma, Open-Angle; Ocular Hypertension
Intervention: brimonidine tartrate/timolol maleate Ophthalmic Solution (Drug)
Phase: N/A
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan
Summary
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and
efficacy of Combigan® (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients
with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta
blockers treated as per standard of care in clinical practice.
Clinical Details
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Percentage of Participants Reporting Adverse EventsPercentage of Participants With Overall Improvement From Baseline in Intraocular Pressure (IOP)
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with Open Angle Glaucoma or Ocular Hypertension treated with Combigan®
Ophthalmic Solution as standard of care in clinical practice.
Exclusion Criteria:
- None.
Locations and Contacts
Seoul, Korea, Republic of
Additional Information
Starting date: January 2009
Last updated: February 25, 2014
|
